Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells

Cancer J. 2019 May/Jun;25(3):208-216. doi: 10.1097/PPO.0000000000000379.


Multiple myeloma is still an incurable malignancy despite the many new therapies approved over the last decade and therefore represents a significant unmet medical need. To address this need, adoptive cellular therapies using chimeric antigen receptor (CAR) T-cells are being explored in clinical investigations. The number of CAR T-cell trials for multiple myeloma has increased exponentially over the past few years. Although the data are preliminary at this time, the results have garnered much enthusiasm in the field. Immune therapies targeting B-cell maturation antigen have been the most widely developed, and much of these early data were presented at the recent American Society of Hematology 2018 meeting. Here we review the available data for anti-B-cell maturation antigen CAR T-cell therapies and discuss next steps as the field progresses forward.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • B-Cell Maturation Antigen / antagonists & inhibitors
  • B-Cell Maturation Antigen / immunology*
  • B-Lymphocytes / immunology*
  • B-Lymphocytes / metabolism*
  • Biomarkers, Tumor
  • CD28 Antigens / immunology
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Mice
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / metabolism*
  • Multiple Myeloma / therapy
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism*
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / metabolism*
  • Treatment Outcome
  • Tumor Necrosis Factor Receptor Superfamily, Member 9 / metabolism


  • B-Cell Maturation Antigen
  • Biomarkers, Tumor
  • CD28 Antigens
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • Tumor Necrosis Factor Receptor Superfamily, Member 9